☰

Geoffrey Alexander Smith - Publications

Affiliations: 
University of California, San Francisco, San Francisco, CA 
Area:
Chemical Biology
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Smith GA, Levinson AL, Galvin RT, Lalor LE, McCalmont T, Wang L, Geis MC, Odegaard K, Hupp M, Maguiness S, Turcotte LM, Cordoro KM, Hermiston ML. Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients. Journal of Pediatric Hematology/Oncology. PMID 32852399 DOI: 10.1097/Mph.0000000000001921  0.412
2018 Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. PMID 29622655 DOI: 10.3324/Haematol.2017.174482  0.541
2017 Smith GA, Taunton J, Weiss A. IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells. Science Signaling. 10. PMID 29259099 DOI: 10.1126/scisignal.aan4931  0.397
2017 Smith GA, Taunton J, Weiss A. IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells. Science Signaling. 10. PMID 29259099 DOI: 10.1126/Scisignal.Aan4931  0.625
2017 Smith GA, Taunton J, Weiss A. IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells. Science Signaling. 10. PMID 29259099 DOI: 10.1126/scisignal.aan4931  0.397
2017 Smith GA, Taunton J, Weiss A. IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells. Science Signaling. 10. PMID 29259099 DOI: 10.1126/scisignal.aan4931  0.397
2017 Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey D, Hermiston ML. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. PMID 28484265 DOI: 10.1038/Leu.2017.136  0.589
2017 Au-Yeung BB, Smith GA, Mueller JL, Heyn CS, Jaszczak RG, Weiss A, Zikherman J. IL-2 Modulates the TCR Signaling Threshold for CD8 but Not CD4 T Cell Proliferation on a Single-Cell Level. Journal of Immunology (Baltimore, Md. : 1950). PMID 28159902 DOI: 10.4049/Jimmunol.1601453  0.573
2016 Yang Z, Robinson MJ, Chen X, Smith GA, Taunton J, Liu W, Allen CD. Regulation of B cell fate by chronic activity of the IgE B cell receptor. Elife. 5. PMID 27935477 DOI: 10.7554/Elife.21238  0.577
2016 Smith GA, Uchida K, Weiss A, Taunton J. Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nature Chemical Biology. PMID 27018889 DOI: 10.1038/Nchembio.2056  0.626
2016 Yang Z, Robinson MJ, Chen X, Smith GA, Taunton J, Liu W, Allen CDC. Author response: Regulation of B cell fate by chronic activity of the IgE B cell receptor Elife. DOI: 10.7554/Elife.21238.020  0.525
2016 Delgado-Martin C, Shimano K, Zinter MS, Wahlstrom JT, Smith GA, Taunton J, Winter SS, Roderick JE, Kelliher M, Horton TM, Wood BL, Teachey DT, Hermiston ML. JAK/STAT Pathway Inhibition Reverts IL7-Induced Glucocorticoid Resistance in a Subset of Human T-Cell Acute Lymphoblastic Leukemia Blood. 128: 3963-3963. DOI: 10.1182/Blood.V128.22.3963.3963  0.579
2016 Lam C, Murnane M, Smith GA, Taunton J, Aftab BT, Wiita AP. Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Though Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma Blood. 128: 2098-2098. DOI: 10.1182/Blood.V128.22.2098.2098  0.549
2015 Carelli JD, Sethofer SG, Smith GA, Miller HR, Simard JL, Merrick WC, Jain RK, Ross NT, Taunton J. Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex. Elife. 4. PMID 26651998 DOI: 10.7554/Elife.10222  0.489
2015 Carelli JD, Sethofer SG, Smith GA, Miller HR, Simard JL, Merrick WC, Jain RK, Ross NT, Taunton J. Author response: Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex Elife. DOI: 10.7554/Elife.10222.027  0.495
Show low-probability matches.